Partner Therapeutics
Lexington, MA, United StatesIndustry
Partner Therapeutics markets a drug approved for hematopoietic acute radiation syndrome. CBRNE-relevant work is a notable product line according to its website. It is headquartered in Lexington, MA, United States.
What it does
Threats covered
Categories
Profile
Partner Therapeutics, based in Lexington, Massachusetts, develops and commercialises Leukine (sargramostim), a recombinant human GM-CSF. The US Food and Drug Administration approved Leukine in 2018 to increase survival in people exposed to myelosuppressive doses of radiation, the haematopoietic subsyndrome of acute radiation syndrome.
More profile
Its orphan drug exclusivity for that use ended on 29 March 2025, according to the FDA orphan drug database. Under contract 75A50124C00061, awarded on 24 September 2024 for 12.99 million dollars and modified through August 2025, the Biomedical Advanced Research and Development Authority funded a Phase 2 study of Leukine in sepsis.
A separate HHS contract, 75A50323F80027, awarded on 26 September 2023 and modified through March 2026, covers Leukine manufacturing.
Ownership
Privately held; ownership not read
Parent: none identified
Sources (5)
- https://www.partnertx.com/partner-therapeutics-ptx-announces-us-fda-approval-of-leukine-sargramostim-for-the-treatment-of-acute-radiation-syndrome/
- https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=541816
- https://www.prnewswire.com/news-releases/barda-and-partner-therapeutics-continue-partnership-around-development-of-leukine-sargramostim-rhu-gm-csf-to-potentially-improve-patient-care-for-sepsis-302347356.html
- https://besagov.com/contracts/75A50124C00061
- https://besagov.com/contracts/75A50323F80027
Not verified or not found
- Founding year and ownership: not found.
- Value of the manufacturing contract: not read.
- Whether the sheet's chemical agent and haemorrhagic fever threat tags have any basis: not confirmed.
Questions
What does Partner Therapeutics do?
Partner Therapeutics markets a drug approved for hematopoietic acute radiation syndrome. CBRNE-relevant work is a notable product line according to its website.
Where is Partner Therapeutics based?
HQ (as found): Lexington, MA. HQ country: US.
Who owns Partner Therapeutics?
Privately held; ownership not read. Parent: none identified
Profiles are compiled from public sources and sampled-checked, not fully audited. Last verified 17 October 2026. Report a correction